Rhonda Farnum Sells 4,000 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. The trade was a 1.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Rhonda Farnum also recently made the following trade(s):

• On Monday, November 11th, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00.

Theravance Biopharma Stock Performance

Theravance Biopharma stock opened at $10.47 on Friday. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $10.90. The stock’s 50 day moving average is $9.45 and its 200 day moving average is $8.91.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). The company had revenue of $16.87 million during the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same period in the prior year, the company posted ($0.17) earnings per share. On average, research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Institutional Trading of Theravance Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of Theravance Biopharma by 21.1% in the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 3,349 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Theravance Biopharma by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock valued at $2,151,000 after acquiring an additional 7,620 shares in the last quarter. Barclays PLC lifted its position in Theravance Biopharma by 279.9% in the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock valued at $529,000 after acquiring an additional 48,316 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Theravance Biopharma during the 3rd quarter valued at $251,000. Finally, XTX Topco Ltd increased its holdings in shares of Theravance Biopharma by 34.5% in the 3rd quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 5,243 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.